FDA approval expected for expanded use of Zevalin

09/4/2009 | Reuters

Analysts are expecting the FDA to approve the use of Spectrum Pharmaceuticals' cancer drug Zevalin as a first-line treatment for non-Hodgkin's lymphoma. The drug currently is approved as treatment for relapsed or refractory NHL. The FDA is set to hand down its decision on Monday.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN